Novo Nordisk submits Ozempic high-dose 2.0mg in the United States: for intensive treatment

Novo Nordisk recently announced that it has resubmitted a label extension application to the U.

Ozempic is a once-a-week glucagon-like peptide 1 (GLP-1) analogue.

In China, Novotel® (Ozempic, 1.

In January 2021, Novo Nordisk submitted a semaglutide 2.

The semaglutide 2.

Two statistical methods were used in the trial: (1) Based on treatment policy estimand, which means that all patients adhere to the study drug treatment and do not use other antidiabetic drugs for the treatment effect; (2) Based on the treatment policy Evaluation (treatment policy estimand), that is, regardless of treatment compliance, regardless of whether other antidiabetic drugs are initiated.

SUSTAIN FORTE test data

The results of the test were announced in November 2020.

In this trial, both doses of semaglutide were shown to be safe and well tolerated.

Semaglutide is a human glucagon-like peptide-1 (GLP-1) analogue, which promotes insulin secretion and inhibits glucagon secretion through a glucose concentration-dependent mechanism, which can make type 2 diabetes mellitus The patient's blood glucose level has improved significantly and the risk of hypoglycemia is low.

In China, the number of diabetic patients exceeds 129.

As a blockbuster GLP-1 product administered once a week, Novotel® uses breakthrough technology to extend the half-life to 7 days, achieve once a week dosing, powerfully control sugar, accurately meet standards, and benefit from comprehensive cardiovascular metabolism.

Original source: Novo Nordisk resubmits once-weekly semaglutide 2.

This article is from Bio Valley, for more information, please download the Bio Valley APP (http://